EFFECT OF PREGNANE XENOBIOTIC RECEPTOR ACTIVATION ON INFLAMMATORY BOWEL DISEASE TREATED WITH RIFAXIMIN

Y C Wan, T Li, Y-D Han, H-Y Zhang, H Lin, B Zhang

Article ID: 5803
Vol 29, Issue 2, 2015
DOI: https://doi.org/10.54517/jbrha5803
Received: 9 July 2015; Accepted: 9 July 2015; Available online: 9 July 2015; Issue release: 9 July 2015

Abstract

The causes and pathogenesis of Inflammatory Bowel Disease (IBD) are still not clearly understood. This study aims to prove the important role of rifaximin played in inflammatory reaction caused by abnormity of the intestinal mucosal immune system. Intestinal microflora can greatly promote and maintain the inflammatory reaction of IBD, therefore, antibiotics can be used to treat IBD. Rifaximin is a medicine usually used for local intestinal infection. Many clinical and basic studies have shown that both a single application of rifaximin and the joint application with other medicines could achieve a good efficacy. This paper studied the activation of Pregnane Xenobiotic Receptor (PXR) in treating IBD with rifaximin and analyzed its efficacy in IBD when PXR was involved in the transport of medicine and metabolism. The results prove that rifaximin can not only serve as an anti-microbial drug, but can activate PXR and actually weaken the reaction of IBD. Thus it is safe to say that rifaximin has great potential in treating IBD.


Keywords

rifaximin;PXR;IBD;activation


References

Supporting Agencies



Copyright (c) 2015 Y C Wan, T Li, Y-D Han, H-Y Zhang, H Lin, B Zhang




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).